TPPB modulates PKC activity to attenuate neuroinflammation and ameliorate experimental multiple sclerosis
Shruthi Shanmukha, Wesley H. Godfrey, Payam Gharibani, Judy J. Lee, Yu Guo, Xiaojing Deng, Paul A. Wender, Michael D. Kornberg, Paul M. Kim
This study shows TPPB, a new PKC modulator, reduces neuroinflammation and promotes CNS repair in experimental MS by targeting innate immune cells.
bioRxiv · Feb 2, 2024Immunology